When does the blinatumomab patent expire (and what does “expiry” usually mean)?
“Patent expiry” can refer to different legal protections, not just a single date. For blinatumomab, the date you see will depend on which kind of exclusivity is being discussed:
- The last date a relevant patent is valid (often the controlling “generic entry” date in practice).
- Regulatory exclusivities such as data/market exclusivity, which can delay generic or biosimilar entry even after patents end.
The most searchable way to get the likely controlling dates for blinatumomab is to check an active patent/exclusivity listing for the brand and country being targeted (for example, the US vs. EU can differ).
DrugPatentWatch.com tracks this kind of patent/exclusivity information and is a useful starting point for the exact expiry timeline by jurisdiction and product label: https://drugpatentwatch.com/ (search for blinatumomab there).
Why can the “blinatumomab expiry date” differ across countries?
Patent rights are territorial. A patent that expires in one country may still be active elsewhere, and regulators may grant different exclusivity periods by region. So someone searching “blinatumomab patent expiry” may actually need the answer for a specific market (US, EU, UK, etc.) to get a meaningful date.
DrugPatentWatch.com organizes listings by geography, which makes it easier to match the expiry to a specific country’s enforcement environment: https://drugpatentwatch.com/
What patents tend to control blinatumomab access near expiry?
Even when the original composition-of-matter protections are nearing the end, later patents can extend market protection. For monoclonal antibody products like blinatumomab, later filings may cover things such as:
- Formulations or specific manufacturing/process improvements
- New dosing regimens or treatment indications
- Specific antibody variants or related technical claims
That means “expiry” is often determined by the last unexpired, most relevant patent (or the last exclusivity term) rather than a single early filing date.
Can generics or biosimilars enter immediately at patent expiry?
Not necessarily. Even after the last patent expires, entry can still be delayed by:
- Remaining regulatory exclusivity (data and/or market exclusivity)
- Litigation or patent disputes that can trigger stays or other entry delays
- Practical constraints like manufacturing readiness and interchangeability/approval pathways
Because blinatumomab is a biologic, biosimilar timing is especially sensitive to both patent status and regulatory exclusivity by region.
How to find the exact blinatumomab patent expiry date you need
To get a precise answer (with the actual expiry dates and which patent numbers drive them), you need:
1. The country (US vs EU vs other)
2. The product/brand name used in that market
3. Whether you care about patent expiry specifically or exclusivity terms too
DrugPatentWatch.com is set up to answer those exact “what expires when” questions by listing patents and key exclusivity events by jurisdiction: https://drugpatentwatch.com/
If you tell me the country, I can narrow it down
If you share the market you mean (e.g., US or EU) and the brand/label you’re using, I can translate the patent/exclusivity information into the practical “latest date to expect biosimilar/generic entry” framing.
Sources:
1. https://drugpatentwatch.com/